Changes in skin discoloration according to clofazimine dosage in nontuberculous mycobacterial pulmonary disease
- 11 June 2024
- journal article
- case report
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (1) , 102441
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Why do we use 100 mg of clofazimine in TB and NTM treatment?Journal of Antimicrobial Chemotherapy, 2024
- Clofazimine‐induced cutaneous hyperpigmentation as a source of stigma in the treatment of leprosy: A cross‐sectional studyTropical Medicine & International Health, 2024
- Treatment Outcomes of Clofazimine-Containing Regimens in Severe Mycobacterium avium Complex Pulmonary DiseaseOpen Forum Infectious Diseases, 2023
- Clofazimine: A journey of a drugBiomedicine & Pharmacotherapy, 2023
- Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial InfectionAntimicrobial Agents and Chemotherapy, 2022
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice GuidelineClinical Infectious Diseases, 2020
- The Physicochemical Basis of Clofazimine-Induced Skin PigmentationJournal of Investigative Dermatology, 2018
- Facial L*a*b* values and preferred base makeup products among native Korean women: a clinical studyBiomedical Dermatology, 2017
- Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and ClarithromycinAntimicrobial Agents and Chemotherapy, 2016
- Role of Clofazimine in Management of Reactions in LeprosyIndian Journal of Drugs in Dermatology, 2015